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Abstract
Treatment of functional gastrointestinal disorders remains difficult with many very different
approaches showing similar response rates, regardless of whether they target luminal contents (e.g.,
presumed bacterial overgrowth), signaling within the gut wall (e.g., serotonin agonists or antagonists)
or processing in the brain (e.g., cognitive behavioral therapy). Discrepancies between recent clinical
trials and a meta-analysis have forced us to re-examine the use of antidepressants. Other studies have
looked beyond the traditional drug therapies and have suggested other options such as dietary
interventions and communication strategies that address relevant disease mechanisms and enable us
to understand patient concerns, with the ultimate goal being to individualize and thus improve
treatment outcomes.
Introduction and context
Symptoms of irritable bowel syndrome (IBS) are
among the most common gastrointestinal complaints
and lead to millions of consultative visits each year.
While the third iteration of the Rome Consensus
Conference provided yet another approach to posi-
tively diagnose functional illnesses, many physicians
continue to see and approach IBS as a diagnosis of
exclusion [1]. Once a diagnosis is made, we have to
think about therapy, which may range from antibiotics
for presumed small bowel bacterial overgrowth to
serotonergic agonists or antagonists, depending on
predominant symptoms and physician or patient
preference. With spiraling healthcare costs and a highly
prevalent syndrome, we need to ask ourselves whether
we should standardize care and, in doing so, perhaps
deliver more for less.
Recent advances
This call for standardized approaches and quality
benchmarks led to development of guidelines that
typically rely on evidence-based medicine and its
primary tool, the meta-analysis. One such meta-analysis
recently examined the utility of antidepressant medica-
tions in IBS. Many physicians use antidepressants when
treating patients with functional bowel disorders.
Mechanistic studies showing the influence of anxiety
and/or hypervigilance on IBS symptoms may provide a
rationale for this approach. Yet, prior studies have
shown conflicting results, which could arguably be due
to limited power and thus be clarified with a meta-
analysis. A team of investigators thus compiled data
from all published studies (identifying 13 studies that
compared antidepressants with placebo) and concluded
that antidepressants are effective in the treatment of IBS
[2]. Although statistically convincing, a purely numer-
ical approach computing an average across very
different studies will gloss over any remaining con-
ceptual concerns. One of the studies supporting the
utility of these agents came from Iran, an area with male
predominance in IBS, quite distinct from what physi-
cians see in the US and European countries. The dosages
of tricyclics vary five- to ten-fold, with the best effects
seen in studies with the lowest dose. So, can we truly
attribute such effects to the pharmacology of a
medication and recommend a specific intervention
(drug) if the effects cannot be explained by known
mechanisms of action? This question becomes even
more important when we look at negative results of
recent trials examining the effects of citalopram in
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children with functional disorders [3,4]. Both trials
were negative, not showing a difference between the
active agent and placebo. Interestingly, pediatric
patients showed impressive improvements in both
arms (amitriptyline and placebo), demonstrating the
power of placebo. Recently, a study did suggest that
imipramine may be effective in the treatment of IBS [5],
however, another demonstrated no significant benefit
for paroxetine [6], further highlighting the differences
in the results within this field. So, why do we see
discrepancies between these studies and the meta-
analysis? Perhaps if rigor went beyond methodological
approaches and transparency to include conceptual
assessments, less disparity would be seen. IBS is defined
by a wide range of symptoms with likely very different
pathophysiologies. It may be a clinically useful label,
but the term describes a syndrome, not disease
mechanisms. Rather than relying on algorithmic
approaches that presume similar disease mechanisms
and applying similar treatments to every person, no
matter whether diarrhea, constipation, bloating or pain
predominate, we need to practice ‘personalized’ med-
icine. In this context, one may well use antidepressants,
basing decisions on the relative contribution of affect
and choosing an agent that fits best in terms of effect
and side-effect profile.
The study by Saps and colleagues [4] highlighted the
placebo effect, which in most large IBS trials is lower
than in this study, but still ranges around 40%. The
importance of placebo responses has triggered inves-
tigations into the different components of this power-
ful effect. An interesting study focused on us, the
healthcare providers. The training we go through
largely focuses on the content of our discussions:
what is going on, what treatments we recommend and
why we suggest them, rather than how we relay that
information to the patient. As part of a trial on
acupuncture in IBS, a team of investigators paired
sham treatment with different communicative strate-
gies [7]. One group met a qualified therapist who
explained the treatment plan, the other talked to a
person who employed empathy, active listening and
instilled confidence. Active listening, empathy and
confidence ‘augmented’ the placebo effect of acupunc-
ture alone, and therefore may matter more than the
technical competence that we can claim as certified
specialists [7]. The results remind us that therapy starts
even before the first pill has been taken. Our
interactions with IBS patients strongly influence the
effect of our interventions. Such findings may well
confirm what we already thought, yet, even if the
results may not surprise us, we as healthcare providers
should more effectively employ these communicative
skills, as patients seemingly continue to leave our
offices not feeling listened to, not understanding their
illness or not feeling understood [8,9]. In a small
study, Collins et al. [8] examined whether expectations
were met during consultative visits with gastroenterol-
ogists. Despite a focus on physicians with special
interest and expertise in functional bowel diseases,
many patients remained unsure or unconvinced about
their diagnosis. Halpert and colleagues [9] chose a
different approach and surveyed IBS patients using the
internet. Most participants looked for education,
explanation, empathy and engaged, active listening
from physicians, mirroring the very components that
contribute to the placebo response. Unfortunately,
they also saw most healthcare providers as lacking in
these very domains. Perhaps these studies give us a
benchmark for quality improvements that are more
applicable than those one can obtain from meta-
analyses.
If the patients or physicians do not want to use
pharmacotherapy, there are other options available,
ranging from herbal remedies to dietary changes and
psychologically-based interventions. When considering
food intake, high-fiber diets seem to be indelibly
linked to improvements in IBS, especially IBS coexist-
ing with constipation, with many reviews and books
recommending it as one of the pillars of IBS manage-
ment. But does it truly improve patients’ quality of life,
which should be our primary goal in persons with
functional gastrointestinal disorders? A recent study
demonstrated that insoluble fiber (bran) was not better
than placebo, and although soluble fiber (psyllium)
transiently helped, this benefit was lost at the end of
the 3-month study [10]. The minor and brief statistical
difference does not translate into clinical relevance,
especially considering the chronic nature of IBS. The
results should prompt us to look for correlations
between a patient’s symptoms and their intake and
output (or outcome) before automatically recommend-
ing changes in fiber intake. Fiber intake is only one of
the many complex components that make up our diet,
so we should not stop obtaining information about
other food and drink intake, or promoting healthy
nutrition, and should perhaps even think about fiber as
a ‘prebiotic.’ Yet, this study should lead us to question
the seemingly automatic assumption that increasing
fiber intake will improve IBS.
Besides fiber, intake of other foods can also affect IBS
symptoms, with many patients reporting intolerances
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to find an objective correlate for such subjective
intolerances and examined the role of food allergies
in IBS [11]. Using elimination diets and food
challenges, about one-third of their patients reacted
to cow milk or wheat protein. Roughly half of these
patients may have suffered from a true food allergy,
which was operationally defined by activation of
basophils in vitro. Thus, food allergies may not be
very common in IBS patients, but this study at least
suggests that they may be more common than other
illnesses often associated with IBS, such as celiac
disease. The basophil activation assay is not widely
available and confirmatory studies are certainly
needed. However, if proven to be effective, we may
n e e dt om a k eu s eo fs t r a t e g i e ss u c ha st h i sa s s a y
because patient history, effects of elimination diets and
food challenge, as well as serum IgE levels against
suspected antigens, poorly predict the potential allergic
basis of food intolerance. If carbohydrates from
fructose and gluten-containing substances do indeed
significantly contribute to IBS symptoms, as this and
some other studies of elimination diets suggest, one
could take a different approach and eliminate carbo-
hydrates completely. In a small, uncontrolled study,
Austin and colleagues [12] asked patients with
refractory functional diarrhea to follow a strict carbo-
hydrate exclusion diet. The rigid approach was
difficult, required implementation through a clinical
research center, prompted several drop outs and may
not be desirable as it is, by definition, nutritionally
imbalanced. However, it also led to improvement in
more than two-thirds of those who complied. While
the popularity of the Atkins and South Beach diets may
have dropped in recent years, less stringent strategies
may not be quite as effective but could be more easily
implemented, still resonate with many patients and
may well provide secondary benefits in diarrhea-
predominant IBS patients by targeting the spreading
obesity epidemic [12].
Implications for clinical practice
In 2010, we may need to split more and look to original
data, rather than lumping and considering only the
meta-analyses. Paying attention to the patient’s primary
symptoms and their main concerns should be made.
The contribution of dietary or other lifestyle choices to
their symptoms should be considered, as should the
role of affect. While trying to obtain this information,
physicians need to focus on more than just the content
of their discussion and hone in on communicative
strategies that may not only increase patients satisfac-
tion, but also improve outcome. Clinical trials have to
use rigor and systematic strategies to test hypotheses
and understand and/or treat possible mechanisms of
disease. In poorly understood complex syndromic
illnesses with divergent clinical manifestations and
likely divergent underlying mechanisms such as IBS,
the clinician may need to abandon evidence-based
medicine and rely instead on individualized approaches
aimed at increasing quality of life.
Abbreviation
IBS, irritable bowel syndrome.
Competing interests
The author declares that he has no competing interests.
References
1. Spiegel BMR, Farid M, Esrailian E, Talley J, Chang L: Is irritable bowel
syndrome a diagnosis of exclusion? A survey of primary care
providers, gastroenterologists, and IBS experts. Am J Gastro-
enterol 2010, 105:848-58.
2. Ford AC, Talley NJ, Schoenfeld PS, Quigley EMM, Moayyedi P:
Efficacy of antidepressants and psychological therapies in
irritable bowel syndrome: systematic review and meta-
analysis. Gut 2009, 58:367-78.
3. Ladabaum U, Sharabidze A, Levin TR, Zhao WK, Chung E, Bacchetti P,
Jin C, Grimes B, Pepin CJ: Citalopram is not effective therapy for
non-depressed patients with irritable bowel syndrome. Clin
Gastroenterol Hepatol 2010, 8:42-8.
F1000 Factor 3.0 Recommended
Evaluated by Klaus Bielefeldt 09 Oct 2009
4. Saps M, Youssef N, Miranda A, Nurko S, Hyman P, Cocjin J,
Di Lorenzo C: Multicenter, randomized, placebo-controlled
trial of amitriptyline in children with functional gastrointest-
inal disorders, gastroenterology. Gastroenterology 2009,
137:1261-9.
F1000 Factor 6.4 Must Read
Evaluated by Klaus Bielefeldt 27 Jul 2009, Jon Markowitz 26 Oct
2009
5. Abdul-Baki H, El Hajj II, Elzahabi L, Azar C, Aoun E, Skoury A,
Chaar H, Sharara AI: A randomized controlled trial of
imipramine in patients with irritable bowel syndrome. World
J Gastroenterol 2009, 15:3636-42.
6. Masand PS, Pae CU, Krulewicz S, Peindl K, Mannelli P, Varia IM,
Patkar AA: A double-blind, randomized, placebo-controlled
trial of paroxetine controlled-release in irritable bowel
syndrome. Psychosomatics 2009, 50:78-86.
7. Kaptchuk TJ, Kelley JM, Conboy LA, Davis RB, Kerr CE, Jacobson EE,
Kirsch I, Schyner RN, Nam BH, Nguyen LT, Park M, Rivers AL,
McManus C, Kokkotou E, Drossman DA, Goldman P, Lembo AJ:
Components of placebo effect: randomised controlled trial in
patients with irritable bowel syndrome. BMJ 2008, 336:999-
1003.
F1000 Factor 6.8 Must Read
Evaluated by Chris Del Mar 17 Apr 2008, Klaus Bielefeldt 24 Apr
2008, Roberto De Giorgio 01 May 2008, Mellar Davis 30 Jun 2008,
Mike Cummings 15 Jul 2008
8. Collins J, Farrall E, Turnbull DA, Hetzel DJ, Holtmann G, Andrews JM:
Do we know what patients want? The doctor-patient
communication gap in functional gastrointestinal disorders.
Clin Gastroenterol Hepatol 2009, 7:1252-1254.e2.
F1000 Factor 3.0 Recommended
Evaluated by Klaus Bielefeldt 21 Jul 2009
Page 3 of 4
(page number not for citation purposes)
F1000 Medicine Reports 2010, 2:50 http://f1000.com/reports/medicine/content/2/509. Halpert A, Dalton CB, Palsson O, Morris C, Hu Y, Bangdiwala S,
Hankins J, Norton N, Drossman DA: Irritable bowel syndrome
patients’ ideal expectations and recent experiences with
healthcare providers: a national survey. Dig Dis Sci 2010, 55:
375-83.
10. Bijkerk CJ, de Wit NJ, Muris JWM, Whorwell PJ, Knottnerus JA,
Hoes AW: Soluble or insoluble fibre in irritable bowel
syndrome in primary care? Randomised placebo controlled
trial. BMJ 2009, 339:b3154.
Changes Clinical Practice
F1000 Factor 6.0 Must Read
Evaluated by Anton Emmanuel 12 Oct 2009
11. Carroccio A, Brusca I, Mansueto P, Pirrone G, Barrale M, Di Prima L,
Ambrosiano G, Iacono G, Lospalluti ML, La Chiusa SM, Di Fede G: A
cytologic assay for diagnosis of food hypersensitivity in
patients with irritable bowel syndrome. Clin Gastroenterol
Hepatol 2010, 8:254-60.
12. Austin GL, Dalton CB, Hu Y, Morris CB, Hankins J, Weinland SR,
Westman EC, Yancy Jr WS, Drossman DA: Av e r yl o w -
carbohydrate diet improves symptoms and quality of life in
diarrhea-predominant irritable bowel syndrome. Clin Gastro-
enterol Hepatol 2009, 7:706-708.e1.
F1000 Factor 3.0 Recommended
Evaluated by Klaus Bielefeldt 18 Mar 2009
Page 4 of 4
(page number not for citation purposes)
F1000 Medicine Reports 2010, 2:50 http://f1000.com/reports/medicine/content/2/50